 The company now expects fiscal 2024 full year adjusted earnings of $2.80 to $2.95 per share, down from the previous estimated $3.20 to $3.35 a share. Pretty significant. This change reflects the challenging pharmacy industry trends and a worse than expected consumer environment, according to the company.